Abstract: A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.

Abstract: A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.

Abstract: A new use of hydroxyurea for preventing, alleviating, or treating systemic inflammatory response syndrome or sepsis is disclosed. Hydroxyurea can control the activity of neutrophils that are immune cells involved in inflammatory mechanisms, and thus can protect an individual from side effects or conditions caused by systemic inflammatory responses which can occur due to exposure to microorganisms such as bacteria or viruses. Thus, a pharmaceutical composition containing hydroxyurea as an active ingredient can prevent, alleviate, or treat systemic inflammatory response syndrome or sepsis in an individual and ultimately can remarkably increase the survival rate of the individual. The composition may be effective in preventing, alleviating, or treating neutrophilia which can occur when exposed to microorganisms such as bacteria or viruses, wherein the viruses include viruses for therapeutic purposes, such as oncolytic viruses as well as pathogenic viruses such as influenza virus or coronavirus.

Abstract: The present invention relates to a tumor-targeting protein or a fragment thereof, an antibody binding thereto and a use thereof. More specifically, the present invention relates to a vector containing a nucleic acid coding for the protein A56 or a fragment thereof, and a use thereof. In addition, the present invention relates to an antibody binding to the protein A56 or a fragment thereof, and a use thereof. The vector containing the nucleic acid coding for the protein A56, a fragment thereof or a mutant thereof of the present invention uses an oncolytic virus as the vector, and thus, when administered in an individual, specifically kills only cancer cells, primarily. In addition, cancer cells which have survived even after being infected with the oncolytic virus express the protein A56 on the cell surfaces thereof, and thus may be targeted for secondary anticancer therapy.

Abstract: The present invention relates to a pharmaceutical composition for treating cancer comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients. The pharmaceutical composition for treating cancer of the present invention, comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients, has an excellent anticancer effect and safety as compared to a conventional case of single administration of an anticancer virus or combined administration of an anticancer virus and an immune checkpoint inhibitor. Accordingly, the pharmaceutical composition for treating cancer of the present invention, comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients, may be effectively used in treating cancer.

Abstract: The present invention relates to a pharmaceutical composition comprising Vaccinia virus and hydroxyurea as active ingredients for prevention or treatment of cancer. The pharmaceutical composition comprising Vaccinia virus and hydroxyurea as active ingredients for treatment of cancer according to the present invention exhibits higher anticancer effects and safety than the conventional administration of Vaccinia virus alone. Therefore, the pharmaceutical composition comprising Vaccinia virus and hydroxyurea as active ingredients according to the present invention may be advantageously used for treating cancer.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a vaccinia virus and a granulopoiesis inhibitor as active ingredients. The pharmaceutical composition for treating cancer, comprising a vaccinia virus and a granulopoiesis inhibitor as active ingredients, of the present invention has a excellent anticancer effect and safety compared to the case of administering only the vaccinia virus. Therefore, the pharmaceutical composition comprising a vaccinia virus and a granulopoiesis inhibitor as active ingredients of the present invention may be efficiently utilized in treating cancer.

Abstract: An oncolytic virus with improved safety and anticancer effects and uses thereof are disclosed. The oncolytic virus contains a recombinant nucleic acid including a nucleotide sequence encoding an effector domain derived from herpes simplex virus thymidine kinase (HSV-TK). The oncolytic virus can express an HSV-TK fragment which contains an effector domain composed of a minimum amino acid sequence capable of phosphorylating GCV or ACV while having no thymidine kinase (TK) activity, or a variant thereof to phosphorylate GCV or ACV, thereby killing cancer cells infected with the oncolytic virus and even neighboring cancer cells.

Abstract: A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.

Abstract: A pharmaceutical composition including an anticancer virus and hydroxyurea as effective components and its use for preventing or treating cancer are disclosed. A method for preventing or treating cancer includes administering an anticancer virus and hydroxyurea as effective components exhibits superior tumor suppression effect as compared to a conventional case where only an anticancer virus is administered; and can kill even the cancer cells that are resistant to anticancer viruses.

Abstract: The present disclosure relates to oncolytic viruses for use transcatheter arterial viroembolization methods. The present disclosure also provides composition with such oncolytic viruses in combination with a biocompatible microparticle or hydrophilic polymer gel agent suitable for active embolization. The present disclosure further provides methods of transcatheter arterial viroembolization using such oncolytic viruses and compositions preferably in a manner that debulks tumor.

Abstract: The present disclosure relates to oncolytic viruses for use transcatheter arterial viroembolization methods. The present disclosure also provides composition with such oncolytic viruses in combination with a biocompatible microparticle or hydrophilic polymer gel agent suitable for active embolization. The present disclosure further provides methods of transcatheter arterial viroembolization using such oncolytic viruses and compositions preferably in a manner that debulks tumor.

Abstract: Provided are a microarray manufactured using a mixture of target probes for drug-resistant HBV detection, quality control probes for controlling quality in probe hybridization and fabrication of microarrays, and negative control probes for determining the presence and ratio of more than one type, i.e., a wild type and a mutant in a codon, measuring a background of non-specific cross-hybridization, and discriminating homozygotes and heterozygotes, and a method of detecting a drug-resistant HBV, controlling the quality of a microarray, determining the presence and ratio of more than one type, and determining positive and false positive probes at the same time using the microarray. The microarray, which includes the target probes for drug-resistant HBV detection, the QC probes, and the negative control probes, can detect a drug-resistant HBV, control quality in fabrication of microarrays and hybridization, determine the presence and ratio of more than one type, i.e.